Added to YB: 2025-11-07
Pitch date: 2025-11-04
QURE [neutral]
uniQure N.V.
-29.18%
current return
Author Info
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.9B
Pitch Price
$27.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.44
P/E
-6.88
EV/Sales
107.85
Sector
Biotechnology
Category
special_situation
FDA flips on uniQure
QURE (update: AMT-130 Huntington's gene therapy faced regulatory setback today, creating uncertainty across HD development landscape. Despite challenges with non-blinded assessments, author remains optimistic about long-term efficacy given direct brain infusion & matched external controls. Expects clearer benefits in years 4-7 follow-up as disease progression becomes more apparent vs placebo effect.
Read full article (3 min)